BRPI0821110A2 - Anticorpo anti nr-10 e uso do mesmo - Google Patents

Anticorpo anti nr-10 e uso do mesmo

Info

Publication number
BRPI0821110A2
BRPI0821110A2 BRPI0821110-8A BRPI0821110A BRPI0821110A2 BR PI0821110 A2 BRPI0821110 A2 BR PI0821110A2 BR PI0821110 A BRPI0821110 A BR PI0821110A BR PI0821110 A2 BRPI0821110 A2 BR PI0821110A2
Authority
BR
Brazil
Prior art keywords
antibody
Prior art date
Application number
BRPI0821110-8A
Other languages
English (en)
Inventor
Taichi Kuramochi
Keiko Kasutani
Souhei Ohyama
Hiroyuki Tsunoda
Tomoyuki Igawa
Tatsuhiko Tachibana
Hirotake Shiraiwa
Keiko Esaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0821110A2 publication Critical patent/BRPI0821110A2/pt
Publication of BRPI0821110B1 publication Critical patent/BRPI0821110B1/pt
Publication of BRPI0821110B8 publication Critical patent/BRPI0821110B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
BRPI0821110A 2007-12-05 2008-12-05 anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo BRPI0821110B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2007315143 2007-12-05
JP2007-315143 2007-12-05
JP2008247425 2008-09-26
JP2008-247425 2008-09-26
PCT/JP2008/072152 WO2009072604A1 (ja) 2007-12-05 2008-12-05 抗nr10抗体、およびその利用

Publications (3)

Publication Number Publication Date
BRPI0821110A2 true BRPI0821110A2 (pt) 2015-07-07
BRPI0821110B1 BRPI0821110B1 (pt) 2021-04-20
BRPI0821110B8 BRPI0821110B8 (pt) 2021-05-25

Family

ID=40717782

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821110A BRPI0821110B8 (pt) 2007-12-05 2008-12-05 anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo

Country Status (17)

Country Link
US (6) US20110129459A1 (pt)
EP (2) EP2236604B1 (pt)
JP (1) JP5682995B2 (pt)
KR (3) KR101840994B1 (pt)
CN (2) CN101939424B (pt)
AU (2) AU2008332271C1 (pt)
BR (1) BRPI0821110B8 (pt)
CA (2) CA2708532C (pt)
DK (1) DK2236604T3 (pt)
ES (2) ES2834741T3 (pt)
HR (1) HRP20151215T1 (pt)
HU (1) HUE025958T2 (pt)
MX (2) MX337081B (pt)
MY (1) MY177564A (pt)
RU (1) RU2531521C2 (pt)
TW (2) TW201634479A (pt)
WO (1) WO2009072604A1 (pt)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
ES2834741T3 (es) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
WO2009072598A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 掻痒症治療剤
SG189775A1 (en) 2008-04-11 2013-05-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
WO2011055550A1 (ja) 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
JP5889181B2 (ja) * 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
NZ603972A (en) 2010-05-11 2014-11-28 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN107629124A (zh) * 2010-12-28 2018-01-26 中外制药株式会社 动物细胞的培养方法
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
MX359235B (es) 2011-09-01 2018-09-20 Chugai Pharmaceutical Co Ltd Metodo para preparar una composicion que comprende anticuerpos altamente concentrados por ultrafiltracion.
US9260531B2 (en) 2012-05-09 2016-02-16 Eli Lilly And Company Anti-c-met antibodies
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
JP6722455B2 (ja) 2013-12-27 2020-07-15 中外製薬株式会社 等電点の低い抗体の精製方法
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
EP3725808A1 (en) 2014-11-21 2020-10-21 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
EA038349B1 (ru) 2014-11-21 2021-08-12 Бристол-Маерс Сквибб Компани Антитела, содержащие модифицированные константные участки тяжелой цепи
WO2016136933A1 (ja) 2015-02-27 2016-09-01 中外製薬株式会社 Ｉｌ－６関連疾患治療用組成物
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
KR102514173B1 (ko) * 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
CN105331703B (zh) * 2015-11-16 2018-08-17 中国农业科学院北京畜牧兽医研究所 一种鉴定或辅助鉴定猪100kg体重眼肌面积的方法及其专用试剂盒
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
CA3010612A1 (en) * 2016-01-08 2017-07-13 Oncobiologics, Inc. Methods for separating isoforms of monoclonal antibodies
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
KR20200132938A (ko) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
US11708186B2 (en) 2018-05-28 2023-07-25 Chugai Seiyaku Kabushiki Kaisha Filling nozzle
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
EP4190354A1 (en) 2020-07-28 2023-06-07 Chugai Seiyaku Kabushiki Kaisha Prefilled syringe preparation with needle, provided with needle shield and including novel modified antibody
AU2020466800A1 (en) 2020-09-01 2023-03-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing IL-31 antagonist as active ingredient
WO2023031770A1 (en) * 2021-08-30 2023-03-09 Galderma Holding SA Treatments for atopic dermatitis
TW202333781A (zh) 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑
TW202340249A (zh) * 2021-12-22 2023-10-16 日商中外製藥股份有限公司 生物活性降低之抗體變體

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS59162441U (ja) 1983-04-14 1984-10-31 千代田紙業株式会社 吹込口を有する重包包装
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
TW205553B (pt) 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH0767688B2 (ja) 1992-01-21 1995-07-26 近畿コンクリート工業株式会社 Ｐｃコンクリートパネル
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
AU689090B2 (en) 1992-12-01 1998-03-26 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
CZ296979B6 (cs) 1994-10-21 2006-08-16 Chugai Seiyaku Kabushiki Kaisha Farmaceutický prípravek pro prevenci nebo lécení Castlemanovy nemoci
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
WO1998003546A1 (en) 1996-07-19 1998-01-29 Amgen Inc. Analogs of cationic proteins
RU2198220C2 (ru) 1996-09-26 2003-02-10 Чугаи Сейяку Кабусики Кайся Антитело против белка, родственного паращитовидному гормону человека, днк, вектор, способ получения и использование антитела
US7365166B2 (en) * 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CN1277632A (zh) 1997-10-03 2000-12-20 中外制药株式会社 天然人源化抗体
PT1074268E (pt) * 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
HUP0101160A2 (hu) 1998-04-03 2001-08-28 Chugai Seiyaku Kabushiki Kaisha Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
AU764653B2 (en) 1998-04-30 2003-08-28 Tanox, Inc. G-CSF receptor agonist antibodies and screening method therefor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1135415B1 (en) * 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
CN1202128C (zh) 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
CA2406650C (en) 2000-05-03 2009-07-21 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
KR100881900B1 (ko) 2001-04-05 2009-02-04 가부시키가이샤 멘에키세이부츠 켄큐죠 항-오스테오폰틴 항체 및 그 용도
ATE471344T1 (de) 2001-04-13 2010-07-15 Biogen Idec Inc Antikörper gegen vla-1
KR20080077295A (ko) 2001-06-22 2008-08-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 세포증식 억제제
DK1476541T3 (da) 2002-01-18 2008-11-03 Zymogenetics Inc Cytokin (zcytor17-ligand)
DK1576112T3 (da) 2002-01-18 2012-06-25 Zymogenetics Inc Cytokin-receptor zcytor17-multimerer
EP1510943A4 (en) 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc INTERACTION PREDICTION DEVICE
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
EP1608684A2 (en) 2003-02-07 2005-12-28 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US20040223970A1 (en) * 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
JP2006521387A (ja) 2003-03-04 2006-09-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 寛容誘導抗原提示細胞による抗原提示の誘導によって自己免疫疾患を治療する方法
DE602004028347D1 (de) 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2004113387A2 (en) 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
JPWO2005035754A1 (ja) * 2003-10-14 2006-12-21 中外製薬株式会社 機能蛋白質を代替する二種特異性抗体
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
EP2270152A1 (en) 2003-12-03 2011-01-05 Chugai Seiyaku Kabushiki Kaisha Expression system using mammalian beta-actin promoter
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
JP2008504289A (ja) * 2004-06-25 2008-02-14 メディミューン，インコーポレーテッド 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加
CN103351434B (zh) 2004-07-15 2015-09-30 赞科股份有限公司 优化的Fc变体
AU2005284006A1 (en) 2004-09-14 2006-03-23 Health Protection Agency Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1805320B1 (en) * 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JPWO2006067847A1 (ja) * 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
AU2005321974B2 (en) 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
ES2557325T5 (es) * 2004-12-28 2023-11-15 Innate Pharma Sa Anticuerpos monoclonales contra NKG2A
US20060275282A1 (en) * 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
US8716451B2 (en) 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
WO2006088855A1 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DK2824183T3 (da) 2005-04-08 2020-09-28 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af bispecifikke antistoffer
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2009510102A (ja) 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション 免疫調節組成物およびその使用
BRPI0617378B8 (pt) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
JP2009528264A (ja) 2006-01-10 2009-08-06 ザイモジェネティクス，インコーポレイティド Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
NZ599035A (en) * 2006-01-12 2013-12-20 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
US8048421B2 (en) * 2006-03-23 2011-11-01 Kyowa Hakko Kirin Co., Ltd. Agonist antibody to human thrombopoietin receptor
PL2004688T5 (pl) * 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
EP3345616A1 (en) * 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
IN2014DN10515A (pt) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
EP2025346B1 (en) * 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
ES2429407T3 (es) * 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
EP2032602B1 (en) * 2006-06-15 2013-03-27 The Board of Trustees of the University of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008100995A1 (en) * 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
RS52345B (en) 2007-02-23 2012-12-31 Schering Corporation ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING
EP2138576A4 (en) * 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd ANTI-CLAUDIN-4 ANTIBODY
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP2155790A1 (en) 2007-05-31 2010-02-24 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
AR068564A1 (es) * 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti- receptor de il-6 (interleuquina 6)
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
PL3059246T3 (pl) 2007-09-26 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Zmodyfikowany region stały przeciwciała
EP2584043A3 (en) * 2007-09-28 2013-10-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having improved kinetics in plasma
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009072598A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 掻痒症治療剤
ES2834741T3 (es) * 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
EP2250279B1 (en) 2008-02-08 2016-04-13 MedImmune, LLC Anti-ifnar1 antibodies with reduced fc ligand affinity
SG189775A1 (en) 2008-04-11 2013-05-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI646193B (zh) * 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
EP2409991B1 (en) * 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2011037158A1 (ja) * 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
JP5889181B2 (ja) * 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US11773173B2 (en) 2015-04-14 2023-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations

Also Published As

Publication number Publication date
EP3095862B9 (en) 2021-04-14
AU2009323249B2 (en) 2012-04-19
US8575317B2 (en) 2013-11-05
TW201634479A (zh) 2016-10-01
CA2708532C (en) 2018-06-05
EP2236604B1 (en) 2016-07-06
TW200932266A (en) 2009-08-01
ES2834741T3 (es) 2021-06-18
MX2010007936A (es) 2010-08-16
US20230183363A1 (en) 2023-06-15
KR20160074019A (ko) 2016-06-27
US20200002429A1 (en) 2020-01-02
BRPI0821110B1 (pt) 2021-04-20
CA2710264A1 (en) 2010-06-10
CA2708532A1 (en) 2009-06-11
CN101952318B (zh) 2014-07-09
MY177564A (en) 2020-09-20
DK2236604T3 (en) 2016-10-03
US9399680B2 (en) 2016-07-26
WO2009072604A1 (ja) 2009-06-11
CA2710264C (en) 2014-10-07
KR20170122860A (ko) 2017-11-06
KR20100097721A (ko) 2010-09-03
KR101840994B1 (ko) 2018-03-21
CN101939424A (zh) 2011-01-05
EP2236604A4 (en) 2012-08-01
AU2008332271B2 (en) 2013-11-07
CN101952318A (zh) 2011-01-19
EP2236604A1 (en) 2010-10-06
RU2531521C2 (ru) 2014-10-20
US20150175704A1 (en) 2015-06-25
JPWO2009072604A1 (ja) 2011-04-28
US20110229459A1 (en) 2011-09-22
JP5682995B2 (ja) 2015-03-11
US20110129459A1 (en) 2011-06-02
CN101939424B (zh) 2016-12-28
RU2010127292A (ru) 2012-01-10
MX337081B (es) 2016-02-10
AU2009323249A1 (en) 2010-06-10
TWI548418B (zh) 2016-09-11
AU2008332271A1 (en) 2009-06-11
KR101643005B1 (ko) 2016-07-28
MX2010006096A (es) 2010-08-04
EP3095862A1 (en) 2016-11-23
HRP20151215T1 (hr) 2015-12-04
EP3095862B1 (en) 2020-09-16
AU2008332271C1 (en) 2014-04-24
US20140039165A1 (en) 2014-02-06
ES2585480T3 (es) 2016-10-06
HUE025958T2 (en) 2016-05-30
BRPI0821110B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
CY2020021I2 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0813514A2 (pt) anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
BRPI0906435A2 (pt) anticorpos anti-cd79b e imunoconjugados e métodos de uso
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI1012676A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1012560A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI0817879A2 (pt) Composições e métodos de uso de anticorpos contra esclerostina
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0820407A2 (pt) Uso de anticorpos anti-cd40
BRPI0820457A2 (pt) Fluidos de ruptura e métodos de uso dos mesmos
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0915717A2 (pt) ferramenta de avaliação de cascalho e métodos de uso
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI1014544A8 (pt) anticorpos anti-il-17f e metodos de uso dos mesmos
CU23871B1 (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1
BRPI0820543A2 (pt) Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0921569A2 (pt) anticorpos para il-6 e uso dos mesmos
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0821027A2 (pt) 4-(4-ciano-2-tioaril) dihidropirimidinonas e seu uso
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF